Trials / Withdrawn
WithdrawnNCT05307627
The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging - A Retrospective Cross-sectional Study Into Off-label Use of LDN
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- AgelessRx · Industry
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- —
Summary
This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.
Detailed description
Long-term (\>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (\<12 months) will be contacted for a retrospective, observational assessment of their health status. Participants will be asked to complete a series of questionnaires assessing their quality of life, general physical and mental health, family history, the occurrence of age-related diseases, and immune status. Additionally, blood tests for immune and longevity markers will be optional for a subset of participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | low-dose naltrexone | LDN doses \<20 mg/day |
Timeline
- Start date
- 2022-03-14
- Primary completion
- 2023-12-14
- Completion
- 2023-12-14
- First posted
- 2022-04-01
- Last updated
- 2024-08-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05307627. Inclusion in this directory is not an endorsement.